Advertisement
What are present hurdles faced with chimeric antigen receptor-engineered T cells (CAR-T cells) therapy?
A. Antigen loss relapse
B. On target/off tumor toxicity
C. Less efficacy in solid tumors
D. All of the above
StatPearls Question of the Week – #9
